TCGA-OR-A5KZ-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.677
- G2M_CHECKPOINT+0.621
- MYC_TARGETS_V1+0.557
- MYC_TARGETS_V2+0.421
- UNFOLDED_PROTEIN_RESPONSE+0.337
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.329
- DNA_REPAIR+0.280
- MITOTIC_SPINDLE+0.256
- WNT_BETA_CATENIN_SIGNALING+0.236
- SPERMATOGENESIS+0.208
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.391
- OXIDATIVE_PHOSPHORYLATION-0.363
- BILE_ACID_METABOLISM-0.355
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.284
- NOTCH_SIGNALING-0.255
- PEROXISOME-0.253
- HEME_METABOLISM-0.242
- FATTY_ACID_METABOLISM-0.239
- INTERFERON_GAMMA_RESPONSE-0.239
- ADIPOGENESIS-0.238
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 5572a203-73b9-4a85-b47d-af228abca5b1 | — | — | 0.842 |
| 2 | MNG495 | — | — | 0.811 |
| 3 | ERR2598166 | fetal | fetal | 0.796 |
| 4 | SRR35579809 | — | B | 0.794 |
| 5 | BS_TZ5D0A7R | EPN | Supratentorial EPN | 0.792 |
| 6 | SJEPD032407_D2.RNA-Seq | EPN | Anaplastic EPN | 0.790 |
| 7 | DRR168611 | — | — | 0.790 |
| 8 | MNG289 | — | — | 0.786 |
| 9 | ERR2598207 | fetal | fetal | 0.781 |
| 10 | SJEPD031102_D1.RNA-Seq | EPN | Supratentorial EPN | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.677 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.621 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.557 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.421 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.337 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.329 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.280 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.256 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.236 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.208 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.177 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.157 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.115 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.104 | Inavolisib | — uncovered |
| HYPOXIA | 0.102 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.076 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.063 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.059 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.058 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.042 | Inavolisib | — uncovered |